The Food and Drug Administration approved an updated label for Kisunla (donanemab-azbt) on July 9, 2025, adding a new, more gradual titration schedule intended to lower the risk of amyloid-related imaging abnormalities with edema or effusion, known as ARIA-E, a swelling side effect associated with amyloid-clearing antibodies. The change, detailed in the revised prescribing information filed with the FDA (BLA 761248, supplement 4), keeps the total dose given over the first three infusions the same but shifts more of it to later doses rather than front-loading it.

The label update rests on TRAILBLAZER-ALZ 6 (NCT05738486), a phase 3b, multicenter, double-blind trial that randomized 843 adults with early symptomatic Alzheimer's disease, meaning mild cognitive impairment or mild dementia with confirmed amyloid buildup on PET scans, to the original dosing regimen or one of three alternative schedules. Results published in the journal Alzheimer's & Dementia found the modified titration arm met its primary goal: ARIA-E occurred in 13.7% of participants at 24 weeks on the modified schedule, versus 23.7% on the standard schedule, a reduction the authors reported as statistically significant. A follow-up analysis of the same trial through 52 weeks, published in the Journal of Prevention of Alzheimer's Disease, found the lower ARIA-E rate persisted and that radiographic severity of ARIA-E was also reduced.

The trial reported that amyloid plaque clearance was similar between groups, roughly 67% reduction from baseline on the modified schedule compared with 69% on the standard schedule at 24 weeks, and reductions in the blood biomarker p-tau217 were also comparable. Eli Lilly, the drug's manufacturer, said no new types of adverse reactions emerged with the modified schedule, though the company and the published trial reports noted higher rates of infusion-related and hypersensitivity reactions in the modified-titration arm, a tradeoff that was not present with the original schedule.

What the FDA action changes, and does not change, is specific: it is a dosing-schedule update for an already-approved drug, not a new approval, and TRAILBLAZER-ALZ 6 was designed to compare ARIA-E rates and amyloid clearance between regimens, not to test whether donanemab slows cognitive decline. The trial was also conducted in a narrowly defined population, adults with early symptomatic Alzheimer's disease and confirmed amyloid pathology, and the published results to date extend to 52 weeks. Whether the modified schedule changes rates of the more severe form of ARIA, called ARIA-H, or affects outcomes beyond a year, are questions the cited publications do not resolve.